Pharvaris says FDA accepts NDA for deucrictibant in hereditary angioedema attacks

• Pharvaris secured FDA acceptance of its NDA for deucrictibant IR 20 mg to treat hereditary angioedema attacks on demand.
• The FDA set a PDUFA target action date of April 23, 2027.
• If cleared, the drug would be the first oral bradykinin B2 receptor antagonist for acute hereditary angioedema attacks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607060650PRIMZONEFULLFEED9757124) on July 06, 2026, and is solely responsible for the information contained therein.